Metabolic factors affecting hepatocellular carcinoma in steatohepatitis
- PMID: 30427105
- PMCID: PMC6617514
- DOI: 10.1111/liv.14002
Metabolic factors affecting hepatocellular carcinoma in steatohepatitis
Abstract
Background & aims: With the rising prevalence of alcoholism, obesity and metabolic syndrome, steatohepatitis will become the leading cause of end-stage liver disease and hepatocellular carcinoma in the United States by 2025. Patients with non-alcoholic steatohepatitis and alcoholic liver disease have similar clinical and histopathological presentations, whether these similarities persist in non-alcoholic steatohepatitis and alcoholic liver disease patients with hepatocellular carcinoma remains unknown.
Methods: A retrospective analysis of the clinical features of adult patients from a large transplant center who underwent liver transplantation for steatohepatitis due to non-alcoholic steatohepatitis and alcoholic causes (alcoholic liver disease) between 1/1/02 and 1/1/12 was performed. Clinical features, explant histopathology, and clinical outcomes were compared.
Results: Hepatocellular carcinoma was present in 80 of 317 patients, who underwent liver transplantation for steatohepatitis with equivalent distribution in non-alcoholic steatohepatitis and alcoholic liver disease patients (24% vs 26%; P = 0.8). On multivariate analysis, significant predictors of hepatocellular carcinoma included age, ethnicity (Hispanic), and diabetes, but not BMI, hypertension or smoking. A lower risk of hepatocellular carcinoma was associated with a clinical history of hyperlipidemia. Clinical parameters were similar between patients with alcoholic liver disease - hepatocellular carcinoma and non-alcoholic steatohepatitis-hepatocellular carcinoma, except sex and presence of metabolic syndrome. non-alcoholic steatohepatitis-hepatocellular carcinoma livers retained histopathological features of non-alcoholic steatohepatitis such as ballooning and Mallory bodies, while alcoholic liver disease-hepatocellular carcinoma livers did not. There were no significant differences in hepatocellular carcinoma recurrence rates or post-transplant overall survival.
Conclusions: We report the largest single-center study evaluating clinical, histopathological and outcome measures of patients undergoing liver transplantation for steatohepatitis. Older patients, diabetics, and Hispanics may warrant more frequent cancer screening due to increased risk of hepatocellular carcinoma.
Keywords: alcoholic liver disease; fatty liver disease; liver cancer; liver transplantation.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Conflict of interest statement
CONFLICT OF INTEREST
The authors do not have any disclosures to report.
Similar articles
-
Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.Liver Transpl. 2017 Aug;23(8):1015-1022. doi: 10.1002/lt.24764. Epub 2017 Jun 26. Liver Transpl. 2017. PMID: 28340509
-
Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.Ann Hepatol. 2019 Nov-Dec;18(6):855-861. doi: 10.1016/j.aohep.2019.06.014. Epub 2019 Sep 6. Ann Hepatol. 2019. PMID: 31543468
-
Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):179-187. doi: 10.1080/17474124.2019.1549989. Epub 2018 Dec 29. Expert Rev Gastroenterol Hepatol. 2019. PMID: 30791782 Review.
-
Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study.J Hepatol. 2019 Aug;71(2):313-322. doi: 10.1016/j.jhep.2019.04.011. Epub 2019 May 7. J Hepatol. 2019. PMID: 31071367 Free PMC article.
-
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103. World J Gastroenterol. 2015. PMID: 25892859 Free PMC article. Review.
Cited by
-
The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients.Biomedicines. 2023 Nov 20;11(11):3096. doi: 10.3390/biomedicines11113096. Biomedicines. 2023. PMID: 38002096 Free PMC article. Review.
-
PKM2 promotes cell metastasis and inhibits autophagy via the JAK/STAT3 pathway in hepatocellular carcinoma.Mol Cell Biochem. 2021 May;476(5):2001-2010. doi: 10.1007/s11010-020-04041-w. Epub 2021 Jan 29. Mol Cell Biochem. 2021. PMID: 33512635
-
Prevalence and Predictors of Nonalcoholic Steatohepatitis Using Multiple Non-Invasive Methods: Data from NHANES III.J Liver. 2020;9(3):244. Epub 2020 Dec 30. J Liver. 2020. PMID: 37786752 Free PMC article.
-
Mechanisms Underlying Hepatocellular Carcinoma Progression in Patients with Type 2 Diabetes.J Hepatocell Carcinoma. 2021 Feb 11;8:45-55. doi: 10.2147/JHC.S274933. eCollection 2021. J Hepatocell Carcinoma. 2021. PMID: 33604315 Free PMC article. Review.
-
The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies.Gastro Hep Adv. 2022 Jul 19;1(6):1049-1087. doi: 10.1016/j.gastha.2022.06.016. eCollection 2022. Gastro Hep Adv. 2022. PMID: 39131247 Free PMC article. Review.
References
-
- Doycheva I, Issa D, Watt KD, Lopez R, Rifai G, Alkhouri N. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in young adults in the United States. J Clin Gastroenterol. 2017;52(4):339–346. - PubMed
-
- Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–555. - PubMed
-
- Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–2273. - PubMed
-
- Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–117. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical